These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29080252)

  • 1. Clinical Evaluation of Tavocept to Decrease Diuresis Time and Volume in Dogs with Bladder Cancer Receiving Cisplatin.
    Henry CJ; Flesner BK; Bechtel SA; Bryan JN; Tate DJ; Selting KA; Lattimer JC; Bryan ME; Grubb L; Hausheer F
    J Vet Intern Med; 2018 Jan; 32(1):370-376. PubMed ID: 29080252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of cisplatin administered with piroxicam in dogs with transitional cell carcinoma of the urinary bladder.
    Greene SN; Lucroy MD; Greenberg CB; Bonney PL; Knapp DW
    J Am Vet Med Assoc; 2007 Oct; 231(7):1056-60. PubMed ID: 17916030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin treatment of transitional cell carcinoma of the urinary bladder in dogs: 18 cases (1983-1993).
    Chun R; Knapp DW; Widmer WR; Glickman NW; DeNicola DB; Bonney PL
    J Am Vet Med Assoc; 1996 Nov; 209(9):1588-91. PubMed ID: 8899023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Piroxicam, mitoxantrone, and coarse fraction radiotherapy for the treatment of transitional cell carcinoma of the bladder in 10 dogs: a pilot study.
    Poirier VJ; Forrest LJ; Adams WM; Vail DM
    J Am Anim Hosp Assoc; 2004; 40(2):131-6. PubMed ID: 15007049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of cisplatin versus firocoxib versus cisplatin/firocoxib in dogs with transitional cell carcinoma of the urinary bladder.
    Knapp DW; Henry CJ; Widmer WR; Tan KM; Moore GE; Ramos-Vara JA; Lucroy MD; Greenberg CB; Greene SN; Abbo AH; Hanson PD; Alva R; Bonney PL
    J Vet Intern Med; 2013; 27(1):126-33. PubMed ID: 23205923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.
    Mohammed SI; Craig BA; Mutsaers AJ; Glickman NW; Snyder PW; deGortari AE; Schlittler DL; Coffman KT; Bonney PL; Knapp DW
    Mol Cancer Ther; 2003 Feb; 2(2):183-8. PubMed ID: 12589035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer.
    Knapp DW; Glickman NW; Widmer WR; DeNicola DB; Adams LG; Kuczek T; Bonney PL; DeGortari AE; Han C; Glickman LT
    Cancer Chemother Pharmacol; 2000; 46(3):221-6. PubMed ID: 11021739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of carbon dioxide laser ablation combined with mitoxantrone and piroxicam treatment in dogs with transitional cell carcinoma.
    Upton ML; Tangner CH; Payton ME
    J Am Vet Med Assoc; 2006 Feb; 228(4):549-52. PubMed ID: 16478428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective evaluation of doxorubicin-piroxicam combination for the treatment of transitional cell carcinoma in dogs.
    Robat C; Burton J; Thamm D; Vail D
    J Small Anim Pract; 2013 Feb; 54(2):67-74. PubMed ID: 23286739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin (cisdiamminedichloroplatinum) for treatment of transitional cell carcinoma of the urinary bladder or urethra. A retrospective study of 15 dogs.
    Moore AS; Cardona A; Shapiro W; Madewell BR
    J Vet Intern Med; 1990; 4(3):148-52. PubMed ID: 2366224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder.
    Knapp DW; Richardson RC; Chan TC; Bottoms GD; Widmer WR; DeNicola DB; Teclaw R; Bonney PL; Kuczek T
    J Vet Intern Med; 1994; 8(4):273-8. PubMed ID: 7983623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs.
    Boria PA; Murry DJ; Bennett PF; Glickman NW; Snyder PW; Merkel BL; Schlittler DL; Mutsaers AJ; Thomas RM; Knapp DW
    J Am Vet Med Assoc; 2004 Feb; 224(3):388-94. PubMed ID: 14765798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcome of partial cystectomy for transitional cell carcinoma of the canine bladder.
    Marvel SJ; Séguin B; Dailey DD; Thamm DH
    Vet Comp Oncol; 2017 Dec; 15(4):1417-1427. PubMed ID: 28217972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxic effects and antitumor response of gemcitabine in combination with piroxicam treatment in dogs with transitional cell carcinoma of the urinary bladder.
    Marconato L; Zini E; Lindner D; Suslak-Brown L; Nelson V; Jeglum AK
    J Am Vet Med Assoc; 2011 Apr; 238(8):1004-10. PubMed ID: 21492043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Piroxicam for bladder cancer.
    Barsanti JA
    J Vet Intern Med; 1995; 9(2):113-4. PubMed ID: 7760310
    [No Abstract]   [Full Text] [Related]  

  • 16. Randomized phase III trial of piroxicam in combination with mitoxantrone or carboplatin for first-line treatment of urogenital tract transitional cell carcinoma in dogs.
    Allstadt SD; Rodriguez CO; Boostrom B; Rebhun RB; Skorupski KA
    J Vet Intern Med; 2015 Jan; 29(1):261-7. PubMed ID: 25619518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder.
    McMillan SK; Boria P; Moore GE; Widmer WR; Bonney PL; Knapp DW
    J Am Vet Med Assoc; 2011 Oct; 239(8):1084-9. PubMed ID: 21985349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of nephrotoxicosis associated with a short-term saline solution diuresis protocol for the administration of cisplatin to dogs with malignant tumors: 61 cases (1987-1989).
    Ogilvie GK; Straw RC; Powers BE; Cooper MF; Withrow SJ
    J Am Vet Med Assoc; 1991 Sep; 199(5):613-6. PubMed ID: 1787122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of nephrotoxicosis associated with a four-hour saline solution diuresis protocol for the administration of cisplatin to dogs with naturally developing neoplasms.
    Ogilvie GK; Straw RC; Jameson VJ; Walters LM; Lafferty M; Powers BE; Henkel SE; Withrow SJ
    J Am Vet Med Assoc; 1993 Jun; 202(11):1845-8. PubMed ID: 8320153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma.
    Henry CJ; McCaw DL; Turnquist SE; Tyler JW; Bravo L; Sheafor S; Straw RC; Dernell WS; Madewell BR; Jorgensen L; Scott MA; Higginbotham ML; Chun R
    Clin Cancer Res; 2003 Feb; 9(2):906-11. PubMed ID: 12576466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.